Ablation Devices Market - By Technology, By Application, By End Use - Global Forecast 2025 - 2034

Ablation Devices Market Size

The global ablation devices market size was valued at around USD 11 billion in 2024 and is estimated to grow at 8.1% CAGR from 2025 to 2034. The rise in demand for ablation procedures is primarily due to chronic diseases such as cancer, orthopedic problems, and particularly cardiovascular diseases.
 

According to The World Health Organization, these diseases are one of the leading global health concerns, accounting for approximately 17.9 million deaths annually. These conditions require prompt and efficient treatment that can be administered through non-invasive means, like surgery, which is sufficiently offered by ablation devices, showcasing their importance in contemporary healthcare systems.
 

Besides chronic diseases, the global surgical procedures tend to increase with the growing population of elderly individuals. The United Nations predicts that by 2050, 1in every 6 people will be over the age of 65, compared to 1 in 11 in 2019. These developments are associated with enhanced longevity and partially attributed to advanced medical care. Many elderly patients prefer less invasive techniques, making the use of ablation devices more popular among these patients.
 

In addition, the development of new devices has enhanced patient care and increased the use of ablation devices due to their functionality via the autonomous workflow of robotics. In October 2023, Boston Scientific announced to receive FDA approval for FARAWAVE NAV Ablation Catheter designed for navigation-enabled paroxysmal atrial fibrillation (AF) ablation. The company also launched FDA 510(k) cleared new PFA integrated FARAVIEW Software, improving procedure vision for ablation compared to the old PFA system. Such a robust pipeline of studies, further, improves the results of treatment interventions and the efficiency of ablation procedures.
 

Ablation devices are medical instruments that use various energy-based technologies to destroy or remove abnormal body tissue. These devices are utilized in minimally invasive procedures for the treatment of ailments such as cancer, cardiac arrhythmias (like atrial fibrillation), chronic pain, and even varicose veins.
 

Ablation Devices Market Trends

• The development of navigation-enabled catheters is enabling the physicians to navigate complex anatomical pathways through sub-millimeter precision.  Catheters equipped with navigation features an ablation device with positional sensors, magnetic tracking devices or electromagnetic field mapping systems that enable simultaneous localization and mapping (SLAM) of the catheter tip and its movement relative to a coordinate system fixed in the environment throughout the procedure.
   
• Further, increasing number of vendors are involved in active clinical trials owing to increasing number of approvals for the ablation technologies. For example, in October 2024, Medtronic announced that the U.S. Food and Drug Administration (FDA) accepted its application for the Affera Mapping and Ablation System which incorporates the Sphere-9 Catheter. This all-in-one apparatus has HD mapping and PF and RF ablation capabilities for treatment of persistent atrial fibrillation (AFib) and RF ablation of CTI-dependent atrial flutter.
   
• Pulsed field ablation (PFA), an emerging non-thermal technique is finding application in the treatment of atrial fibrillation owing to its precision in targeting myocardial cells and preserving the adjacent structures. As per the February 2025 study published by Frontiers in Cardiovascular Medicine, PFA is widely accepted as a feasible option for AF ablation as it demonstrates optimal safety and efficacy outcomes.
   
• Ablation systems are now being fused with real-time imaging systems such as MRI, Ultrasound, Fluoroscopy, and 3D mapping systems. As a result, there is an increase in precision, a decrease in collateral damage, and a reduction in the time taken to complete procedures; this is particularly important in tumor and cardiac ablation.
   

Ablation Devices Market Analysis

Based on technology, the market is segmented into radiofrequency devices, laser/light ablation, ultrasound devices, cryoablation devices, and other technologies. The radiofrequency devices segment dominated the market with the largest revenue share of 49.2% in 2024.
 

• A surge in the number of people suffering from chronic conditions such as cancer, cardiovascular diseases, and other persistent disorders is boosting the need for radiofrequency ablation (RFA) devices.
   
• For instance, as reported by World Health Organization (WHO), approximately 1 out of every 5 people will develop cancer in their lifetime. Approximately 1 out of every 9 men and 1 out of every 12 women are expected to die from the disease as well. These figures emphasize the demand for treatment options such as RFA in chronic disease management.
   
• Furthermore, new developments in RFA, like catheter design, image capture methods, and navigation technologies, have made remarkable progress in making the procedure safer and more effective. These advances ensure optimal results for patients and drive further adoption of RFA devices.
   

Based on application, the ablation devices market is segmented into cardiology, oncology, ophthalmology, gynaecology, urology, cosmetic surgery, and other applications. The cardiology segment dominated the market with the largest revenue of USD 4.5 billion in 2024.
 

• The demand for cardiac ablation procedures, which was valued at USD 3.5 billion in 2022, is driven by the elderly population due to their increased risk of heart diseases. For instance, as per WHO, the global population aged 60 years and older will increase from 12% to 22% of the total population by 2050.
   
• The elderly population suffers from multiple comorbidities, which makes them ideal candidates for minimally invasive cardiac procedures. This shift in population demographics indicates that there will be a consistent increase in the number of procedures performed.
   
• In addition, growing awareness towards the advantages of ablative therapy among patients and other healthcare professionals is also accelerating market expansion. Campaigns raising awareness about treatment options promote proactive treatment and encourage compliance with the prescribed therapies.
   

Based on end use, the ablation devices market is segmented into hospitals, ambulatory surgical centers, and other end users. The hospitals segment dominated the market with the largest revenue of USD 5.5 billion in 2024.
 

• The rising global burden of chronic ailments, especially cardiovascular disease and cancer, is driving the demand for ablation procedures in hospitals. For instance, the Centers for Disease Control and Prevention (CDC) states that coronary heart disease remained the most common form of heart disease and caused about 371,506 deaths in the U.S. in 2022.
   
• These disorders require sophisticated treatment solutions, and ablation devices present efficient therapeutic options that are less invasive. The increasing burden of chronic diseases continues to reinforce the growing integration of ablation devices as a standard treatment devices across the hospital.
   
• Hospitals also emphasize the use of minimally invasive systems due to their benefits such as lower operational and rehabilitation times and shorter length of hospitalization. The use of ablation devices across hospitals also helps to reduce the overall cost of healthcare. As a result, owing to growing emphasis on value-based care, the demand for ablation devices across hospitals is increasing.
   

North America: The U.S. ablation devices market is projected to grow significantly, reaching USD 8.9 billion by 2034.
 

• The U.S. FDA has accelerated the processes for new ablation technologies. This has expedited the development and marketing for advanced devices in the U.S. For instance, in November 2024, Johnson & Johnson declared that the VARIPULSE Platform they developed for drug-refractory paroxysmal AFib was approved by the U.S. FDA. These developments in approval shows an increasing trust in the use of technology for safe and effective ablation procedures.
   
• Moreover, the growing trend of using minimally invasive surgical procedures in the U.S. healthcare system has catalyzed the offering of ablation as a less invasive option to surgery, leading to faster recovery and reduced hospital stay for patients.
   

Europe: The ablation devices market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The UK's aging population is more susceptible to chronic diseases that require surgical interventions. For instance, according to Age UK, in 2023, there were 11 million individuals aged over 65 in England. This number is projected to increase by 10% over the next five years, reaching an additional 1.1 million people, and by 32% by 2043, which equates to an increase of 3.5 million people.
   
• Owing to rising elderly population, the demand for advanced, low risk ablation treatments is increasing, underscoring the need for sophisticated medical technologies in the UK.
   
• Furthermore, funding available in healthcare and investment in medical technologies by the UK government as well as the private sector have also enhanced the access to ablation devices for use in clinics and hospitals.
   

Asia Pacific: Japan ablation devices market is anticipated to witness lucrative growth between 2025 - 2034.
 

• Rising burden of cardiovascular diseases such as atrial fibrillation and coronary artery disease in Japan necessitates advanced procedures like ablation. For instance, according to the National Institutes of Health, approximately 1 to 2 million patients are reported to be suffering from congestive heart failure in Japan, and close to 170,000 patients die from cardiovascular diseases every year.
   
• This emphasizes on Japan’s efficient approach towards the management of these conditions and focuses on the increasing disease burden that Japan's healthcare system faces.
   
• Additionally, patient awareness about cardiovascular treatment options continues to grow in Japan, resulting in higher demand for effective therapies, including ablation procedures. Healthcare providers' educational initiatives enhance patient understanding of treatment benefits.
   

Middle East and Africa: The ablation devices market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• As a part of its long term investment strategy (under Saudi Vision 2030), the government of Saudi Arabia is promoting the developments in the healthcare infrastructure, which include specialized cardiac centers. This provides smooth integration of ablation devices into the healthcare system. 
   
• Additionally, medical technology adoption is being actively encouraged by country’s regulatory authorities through streamlining regulatory process. For example, in January 2024, Imricor Medical Systems, Inc., a worldwide pioneer in real-time iCMR cardiac ablation devices, proclaimed that it had received Medical Device Marketing Authorization (MDMA) from the Saudi Food and Drug Authority (SFDA), which allows them to commence marketing activities within the Saudi Arabia. These advancements in regulation have led to a proportional increase in registered medical device manufacturers in the Saudi Arabia.
   

Ablation Devices Market Share

The market is concentrated and has presence of both large international players and smaller domestic companies. Top 4 companies in the market including Medtronic, Boston Scientific, Abbott Laboratories, and AngioDynamics shared about 60% of the market in 2024. These established players spend extensively on research and development for developing advanced ablation device technologies such as navigation catheters, pulsed field ablation, remote and robotic assistance, and catheter design biomaterials.
 

Further, strategic partnerships with educational and healthcare institutions is also among key strategies, that helps in the implementation of advanced technologies and broader distribution, allowing these companies to meet the growing need for cost-efficient options. Additionally, regulatory support and streamlined approval processes further encourage innovation and offers a competitive edge, strengthening the position of established players in the expanding market. Smaller players focus on low pricing strategies to sustain in the market.
 

Ablation Devices Market Companies

Some of the eminent market participants operating in the ablation devices industry include:

• Abbott Laboratories
• Alcon Laboratories
• Angiodynamics
• Atricure
• Bausch & Lomb
• Biotronik
• Boston Scientific Corporation
• CONMED Corporation
• Elekta
• Ethicon
• Medtronic
• Olympus Corporation
• Varian
   
• Medtronic has expertise in cardiac, pain management, and oncology applications, and offers RF, cryoablation, and microwave ablation systems, that are extensively used for managing cardiac and oncology related complications. The company leverages its advanced navigation tools such as EnSite Precision to offer enhanced accuracy to end users.
   
• Boston Scientific offers one of the first PFA device (using non-thermal ablation) with real-world clinical adoption. The non-thermal ablation helps to reduce the risk of esophageal and phrenic nerve injury. Company also has expertise in developing advanced ablation therapy for use in atrial fibrillation treatment.
   
• Abbott Laboratories offers advanced ablation devices featuring high-resolution, real-time 3D cardiac mapping, that helps the clinicians to localize arrhythmias prior to ablation. The company has extensive sales and service network across developed as well as emerging market, that offers it competitive edge.
   

Ablation Devices Industry News:

• In March 2025, Abbott announced to receive CE Mark in Europe for the Volt PFA System, designed for the treatment of atrial fibrillation. The introduction of Abbott’s Volt PFA system is a significant landmark in the advancement of electrophysiology across Europe. The company plans to further expand the use of Volt in EU markets during the latter half of the year.
   
• In September 2024, Boston Scientific Corporation announced that it received approval from the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for the FARAPULSE Pulsed Field Ablation (PFA) System, indicated for the isolation of pulmonary veins in the treatment of paroxysmal atrial fibrillation (AF) and served as a novel alternative to standard thermal ablation treatments. This approval was expected to enhance Boston Scientific's market presence in Japan.
   
• In March 2023, Medtronic announced to receive CE Mark approval for Affera Mapping and Ablation System, that includes the Sphere-9 Catheter and the Affera Prism-1 Mapping Software, for treating atrial arrhythmias.
   
• In August 2022, Medtronic plc, a global leader in healthcare technology, announced the acquisition of Affera, Inc. This acquisition expanded the company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform, featuring a fully integrated diagnostic, focal pulsed field, and radiofrequency ablation solution. strengthening its position in the cardiac market.
   

The ablation devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Technology

• Radiofrequency devices
• Laser/light ablation
• Ultrasound devices
• Cryoablation devices
• Other technologies

Market, By Application

• Cardiology
• Oncology
• Ophthalmology
• Gynecology
• Urology
• Cosmetic surgery
• Other applications

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Poland
  • Switzerland
  • Netherlands
• Asia Pacific 
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Thailand
  • Indonesia
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • Chile
• Middle East and Africa 
  • Saudi Arabia
  • South Africa
  • UAE
  • Israel